Advancing Early Cancer Detection and Precision Health Management Through DNA Methylation and Liquid Biopsy Technologies
Hsinchu, Taiwan – November 5, 2026
EpiSante Biomedical, a Taiwan-based biotechnology company, participated in SWITCH 2026 (Singapore Week of Innovation and Technology), held from October 27 to 29, 2026, at the Marina Bay Sands Expo & Convention Centre in Singapore.
At this international innovation and technology event, EpiSante Biomedical showcased Taiwan's technological advancements in DNA methylation analysis and liquid biopsy, highlighting the potential of epigenetic technologies in early cancer detection, post-treatment monitoring, and precision health management.
The company was represented by its CEO, Dr. Chang-Yi Lu. During the event, the EpiSante Biomedical team also engaged in exchanges with Dr. Chen-yuan Tung, Representative of the Taipei Representative Office in Singapore, and Ms. Chien-Shu Hung, Chief Secretary of the Hsinchu Science Park Bureau. These interactions reflected Taiwan's commitment to strengthening its presence in the global innovation ecosystem and expanding international collaboration in the biotechnology and healthcare sectors.
Building on More Than Two Decades of Epigenetic Research
EpiSante Biomedical's technological foundation builds upon more than two decades of epigenetic research at Taiwan's Industrial Technology Research Institute (ITRI). The company continues to bridge scientific research, clinical testing, and commercial healthcare applications, with a focus on developing DNA methylation-based diagnostic technologies.
DNA methylation is a key mechanism of epigenetic regulation that reflects changes in gene expression and cellular biological states. Unlike changes in the underlying DNA sequence, DNA methylation patterns can vary with cellular differentiation, aging, environmental exposures, and disease conditions, making them valuable candidates for biomarker research.
With advances in liquid biopsy technologies, the analysis of methylation patterns in circulating cell-free DNA (cfDNA) from blood samples has emerged as an important research direction for early cancer detection and disease monitoring.
By integrating DNA methylation analysis with liquid biopsy technologies, EpiSante Biomedical aims to develop non-invasive testing solutions. These approaches offer potential applications in early cancer risk identification, post-treatment disease monitoring, and the assessment of individual health conditions.
Expanding the Potential of Liquid Biopsy: From Early Cancer Detection to Post-Treatment Monitoring
Conventional cancer diagnosis often relies on medical imaging, tissue biopsies, and other clinical testing methods. Liquid biopsy provides an alternative approach to obtaining disease-related molecular information through blood samples, offering advantages such as relatively convenient sample collection and the potential for repeated monitoring over time.
EpiSante Biomedical continues to invest in DNA methylation-based diagnostic technology, exploring disease-associated methylation biomarkers and their potential applications in three key areas:
- Early Cancer Detection
Investigating the use of cfDNA methylation patterns in blood samples to identify molecular signals associated with cancer, with the goal of advancing early cancer detection technologies.
- Post-Treatment Monitoring
Studying dynamic changes in circulating molecular biomarkers to explore their potential applications in evaluating treatment response and monitoring disease status.
- Precision Health Management
Exploring the relationships between epigenetic information, individual health conditions, aging, and lifestyle factors to support the development of more comprehensive health assessment tools.
These research directions demonstrate that DNA methylation technology is not only an important tool in cancer diagnostic research but may also become a significant technological foundation for future precision health management.
Participating in SWITCH 2026 to Strengthen Taiwan's Global Biotechnology Connections
SWITCH is one of Singapore's major international innovation and technology events, bringing together startups, technology companies, investment institutions, and industry professionals from around the world to facilitate cross-border technology exchange and business collaboration.
Through its participation in SWITCH 2026, EpiSante Biomedical not only presented Taiwan's technological developments in epigenetics and liquid biopsy but also sought to strengthen connections with international biotechnology and healthcare partners, exploring opportunities for future technological collaboration and global market expansion.
As global attention continues to grow around cancer prevention, early detection, and preventive medicine, EpiSante Biomedical remains committed to advancing DNA methylation-based technologies, strengthening its diagnostic platforms, and translating research achievements into clinical applications and commercial opportunities.
EpiSante Biomedical believes that by decoding the epigenetic information within our DNA, healthcare can move beyond diagnosing diseases after they occur toward earlier risk identification and more personalized health assessment.
About EpiSante Biomedical
EpiSante Biomedical is a biotechnology company focused on epigenetic technologies and precision medicine applications. With DNA methylation analysis and liquid biopsy at the core of its technological development, the company is dedicated to advancing non-invasive solutions for early cancer detection, post-treatment monitoring, and precision health management.
Through innovative molecular diagnostic technologies, EpiSante Biomedical aims to create new possibilities in cancer prevention, early detection, and personalized healthcare.
Original Article:Reading Health in Our DNA: EpiSante Biomedical at SWITCH 2026